EMA consults on heart failure medicine

Published: 14-Nov-2012
Cardiovascular

Trials might not adequately reflect impact of these drugs on patients


The European Medicines Agency (EMA) has launched a public consultation on revised guidance for pharmaceutical manufacturers developing acute heart failure drugs.

The changes reflect concern that trials might not adequately reflect the differing impact of these medicines on patients whose overall health and physical characteristics could vary widely.

EMA is inviting comments by 15 April 2013.

See more

You may also like

Cardiovascular

Moderna and Chiesi establish collaboration for mRNA therapeutics

Read more
Moderna will receive $25m upfront and is eligible for more than $400m in development, regulatory, and commercial milestones

Trending Articles

  1. Novasep to manufacture API for heart failure drug for Celladon Signs a multi-million Euro deal with US firm
  2. Pfizer signs deal with Bind Therapeutics To develop and commercialist Accurins using Bind nanoengineering technology
  3. Amgen and Astellas agree alliance in Japan Will focus on co-development of five Amgen medicines in Japan
  4. Rigel to concentrate on three of its leading clinical programmes This will mean cutting its workforce by about 18% or 30 people
  5. Genzyme and Alnylam expand rare genetic diseases collaboration Genzyme becomes major shareholder in the company through a US$700m equity investment

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Cardiovascular

Moderna and Chiesi establish collaboration for mRNA therapeutics

Moderna will receive $25m upfront and is eligible for more than $400m in development, regulatory, and commercial milestones
Ingredients

Vitamin K2 technology wins award for NattoPharma spin-off

Kaydence Pharma has received a start-up award at the BIO International convention
Ingredients

Study: Vitamin K2 deficiency increases cardiovascular stress

Improving vitamin K2 status could benefit arterial stiffening and calcification, reducing cardiovascular complications, new study finds
Drug Delivery

US FDA approves cardiovascular medicine from Baxter

The premixed format of eptifibatide to treat acute coronary syndrome is the first of its kind available in a flexible container
Research & Development

Crown Bioscience expands cardiovascular and metabolic disease research capability

The company offers new non-GLP services and translational rodent models at its expanded site in Louisiana
Research & Development

Axol Bioscience launch Human iPSC-derived Atrial Cardiomyocytes

A consistent and reproducible model for drug development, toxicity testing and disease modelling applications
Research & Development

Domainex expands partnership with ICL to reduce heart muscle damage during heart attacks

The aim is to discover a drug that inhibits the enzyme MAP4K4, which plays a key role in triggering cell death following a heart attack
Subscribe now